<unk>  is an antiviral and protease inhibitor that is FDA approved for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy, including prior null responders, partial responders, and relapsers.   Common adverse reactions include fatigue, anemia, nausea, headache and dysgeusia.
Boceprevir
Simeprevir
Saquinavir
Telaprevir
Abacavir
Tipranavir
Enfuvirtide
Fosamprenavir